| Peter Hanna Gumma, MD | |
|
17187 Schaefer Hwy, Detroit, MI 48235-4132 | |
| (313) 367-2767 | |
| (313) 367-2818 |
| Full Name | Peter Hanna Gumma |
|---|---|
| Gender | Male |
| Speciality | Physical Medicine And Rehabilitation |
| Experience | 19 Years |
| Location | 17187 Schaefer Hwy, Detroit, Michigan |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1255564100 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208100000X | Physical Medicine & Rehabilitation | 4301086814 (Michigan) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Sinai-grace Hospital | Detroit, MI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Michigan Rehabilitation Physicians | 4385824382 | 7 |
| Jawad A Shah, Md Pc | 5799779633 | 59 |
News Archive
The severity of injury and level of impairment - not the workers' legal fees - have the most effect on payout for workers' compensation claims among Illinois construction workers, researchers at the University of Illinois at Chicago School of Public Health have found.
A study published in the February 2013 issue of the Journal of the American Academy of Child and Adolescent Psychiatry found that children and adolescents with major depression or subthreshold forms of bipolar disorder - and who had at least one first-degree relative with bipolar disorder - responded better to a 12-session family-focused treatment than to a briefer educational treatment.
A new study provides the first evidence that the mediator complex subunit 15 (MED15) may play a crucial role in the pathophysiology of head and neck squamous cell carcinoma (HNSCC). MED15 overexpression was found to be associated with higher mortality rates in HNSCC patients with cancer recurrence, particularly in oral cavity/oropharyngeal tumors, according to the study published in The American Journal of Pathology.
Cubist Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has accepted the Company's New Drug Application for its investigational antibiotic tedizolid phosphate (TR-701) with Priority Review. The FDA has assigned a Prescription Drug User Fee Act action date of June 20, 2014. Cubist is seeking FDA approval of tedizolid for the treatment of acute bacterial skin and skin structure infections.
Urgent action is needed to improve outcomes for lung cancer patients, a leading lung cancer expert will explain in a public lecture at the University of Leicester.
› Verified 5 days ago
| Entity Name | Jawad A Shah, Md Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1942402391 PECOS PAC ID: 5799779633 Enrollment ID: O20040413000798 |
News Archive
The severity of injury and level of impairment - not the workers' legal fees - have the most effect on payout for workers' compensation claims among Illinois construction workers, researchers at the University of Illinois at Chicago School of Public Health have found.
A study published in the February 2013 issue of the Journal of the American Academy of Child and Adolescent Psychiatry found that children and adolescents with major depression or subthreshold forms of bipolar disorder - and who had at least one first-degree relative with bipolar disorder - responded better to a 12-session family-focused treatment than to a briefer educational treatment.
A new study provides the first evidence that the mediator complex subunit 15 (MED15) may play a crucial role in the pathophysiology of head and neck squamous cell carcinoma (HNSCC). MED15 overexpression was found to be associated with higher mortality rates in HNSCC patients with cancer recurrence, particularly in oral cavity/oropharyngeal tumors, according to the study published in The American Journal of Pathology.
Cubist Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has accepted the Company's New Drug Application for its investigational antibiotic tedizolid phosphate (TR-701) with Priority Review. The FDA has assigned a Prescription Drug User Fee Act action date of June 20, 2014. Cubist is seeking FDA approval of tedizolid for the treatment of acute bacterial skin and skin structure infections.
Urgent action is needed to improve outcomes for lung cancer patients, a leading lung cancer expert will explain in a public lecture at the University of Leicester.
› Verified 5 days ago
| Entity Name | Michigan Rehabilitation Physicians |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1215240502 PECOS PAC ID: 4385824382 Enrollment ID: O20110208000924 |
News Archive
The severity of injury and level of impairment - not the workers' legal fees - have the most effect on payout for workers' compensation claims among Illinois construction workers, researchers at the University of Illinois at Chicago School of Public Health have found.
A study published in the February 2013 issue of the Journal of the American Academy of Child and Adolescent Psychiatry found that children and adolescents with major depression or subthreshold forms of bipolar disorder - and who had at least one first-degree relative with bipolar disorder - responded better to a 12-session family-focused treatment than to a briefer educational treatment.
A new study provides the first evidence that the mediator complex subunit 15 (MED15) may play a crucial role in the pathophysiology of head and neck squamous cell carcinoma (HNSCC). MED15 overexpression was found to be associated with higher mortality rates in HNSCC patients with cancer recurrence, particularly in oral cavity/oropharyngeal tumors, according to the study published in The American Journal of Pathology.
Cubist Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has accepted the Company's New Drug Application for its investigational antibiotic tedizolid phosphate (TR-701) with Priority Review. The FDA has assigned a Prescription Drug User Fee Act action date of June 20, 2014. Cubist is seeking FDA approval of tedizolid for the treatment of acute bacterial skin and skin structure infections.
Urgent action is needed to improve outcomes for lung cancer patients, a leading lung cancer expert will explain in a public lecture at the University of Leicester.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Peter Hanna Gumma, MD Po Box 93, Fraser, MI 48026-0093 Ph: (313) 367-2767 | Peter Hanna Gumma, MD 17187 Schaefer Hwy, Detroit, MI 48235-4132 Ph: (313) 367-2767 |
News Archive
The severity of injury and level of impairment - not the workers' legal fees - have the most effect on payout for workers' compensation claims among Illinois construction workers, researchers at the University of Illinois at Chicago School of Public Health have found.
A study published in the February 2013 issue of the Journal of the American Academy of Child and Adolescent Psychiatry found that children and adolescents with major depression or subthreshold forms of bipolar disorder - and who had at least one first-degree relative with bipolar disorder - responded better to a 12-session family-focused treatment than to a briefer educational treatment.
A new study provides the first evidence that the mediator complex subunit 15 (MED15) may play a crucial role in the pathophysiology of head and neck squamous cell carcinoma (HNSCC). MED15 overexpression was found to be associated with higher mortality rates in HNSCC patients with cancer recurrence, particularly in oral cavity/oropharyngeal tumors, according to the study published in The American Journal of Pathology.
Cubist Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has accepted the Company's New Drug Application for its investigational antibiotic tedizolid phosphate (TR-701) with Priority Review. The FDA has assigned a Prescription Drug User Fee Act action date of June 20, 2014. Cubist is seeking FDA approval of tedizolid for the treatment of acute bacterial skin and skin structure infections.
Urgent action is needed to improve outcomes for lung cancer patients, a leading lung cancer expert will explain in a public lecture at the University of Leicester.
› Verified 5 days ago
Monica Marie Loving, Physical Medicine & Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 4646 John R St, Detroit, MI 48201 Phone: 313-576-1000 | |
Dr. Medha Shah, MD Physical Medicine & Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 261 Mack Ave, Detroit, MI 48201 Phone: 313-745-2550 | |
Mr. Slawomir Edward Janiszewski, Physical Medicine & Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 4646 John R St, Detroit, MI 48201 Phone: 313-576-3511 | |
Dr. Matthew Thomas Santa Barbara, M.D. Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 2799 W Grand Blvd, Detroit, MI 48202 Phone: 313-916-2181 | |
Abulhasan Sayed, MD Physical Medicine & Rehabilitation Medicare: Medicare Enrolled Practice Location: 261 Mack Ave, Detroit, MI 48201 Phone: 313-745-9733 Fax: 313-745-1063 | |
Ali Ahmad Bitar, MD Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: Rehabilitation Institute Of Michigan, 261 Mack Blvd, Detroit, MI 48201 Phone: 313-966-0544 Fax: 313-745-1065 |